Consensus Acrivon Therapeutics, Inc.

Equities

ACRV

US0048901096

Market Closed - Nasdaq Other stock markets 01:30:00 18/05/2024 am IST			5-day change	1st Jan Change
8.89 ^USD	+3.86%		+1.37%	+80.69%

14/05	Acrivon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
30/04	North American Morning Briefing : More Earnings -2-	DJ

Evolution of the average Target Price on Acrivon Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

dc4757639e51f245c00816194e1437f.XnRrv7msaOePg3tEkzdcbQhkPa-Bdj1gtBLlnW1UQd0.NCdb0e3NOtK_xk529XMUDlIvDcXHRggx41iJ-i85M7g1ESrFyZ0io7nqNg~8e89da60b5148a59f446f850ed612ea1

Analyst Recommendations on Acrivon Therapeutics, Inc.

Ladenburg Thalmann Downgrades Acrivon Therapeutics to Neutral	29/04	MT
Piper Sandler Adjusts Price Target on Acrivon Therapeutics to $30 From $26, Keeps Overweight Rating	25/04	MT
Ladenburg Thalmann Cuts Price Target on Acrivon Therapeutics to $14 From $18, Maintains Buy Rating	05/04	MT
JMP Securities Starts Acrivon Therapeutics With Market Outperform Rating, $14 Price Target	01/03	MT
Maxim Initiates Acrivon Therapeutics at Buy Rating With $24 Price Target	05/23/05	MT
Oppenheimer Initiates Coverage on Acrivon Therapeutics With Outperform Rating, $25 Price Target	02/23/02	MT
BMO Capital Initiates Acrivon Therapeutics at Outperform With $25 Price Target	08/23/08	MT
HC Wainwright Initiates Coverage on Acrivon Therapeutics With Buy Rating, $24 Price Target	20/23/20	MT
Jefferies Starts Acrivon Therapeutics at Buy With $17 Price Target	12/22/12	MT
Piper Sandler Starts Acrivon Therapeutics at Overweight With $25 Price Target	12/22/12	MT
Cowen Starts Acrivon Therapeutics at Outperform	12/22/12	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.89 USD

Average target price

22.12 USD

Spread / Average Target

+148.88%

High Price Target

30 USD

Spread / Highest target

+237.46%

Low Price Target

17 USD

Spread / Lowest Target

+91.23%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Acrivon Therapeutics, Inc.

Ladenburg Thalmann
Piper Sandler
JMP Securities
Maxim
Oppenheimer
BMO Capital
HC Wainwright
Jefferies & Co.
Cowen

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar